Objective To assess whether post-authorisation studies registered with the European Medicines Agency (EMA) adhere to legislation and recommendations to publicly post study protocols and results.
• FY2026 product sales revenue is expected to be approximately NZ$2.4 million, representing an increase of 41% on FY2025, but below the market guidance of NZ$2.8 million . • While a signed sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results